Overview

  • Product nameTranilast
  • Description
    Anti-inflammatory agent
  • Biological descriptionPotent mast cell membrane stabilizer. Exhibits a wide range of anti-inflammatory effects. Inhibits antigen-induced release of cytokines, chemokines and proteases. Able to inhibit angiotensin II induced contractions (IC50 = 36 μM).
  • Purity> 99%

Properties

    Applications

    Our Abpromise guarantee covers the use of ab120643 in the following tested applications.

    The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.

    Application Abreviews Notes
    Functional Studies Use at an assay dependent concentration.

    Tranilast images

    • ab84833 staining Aryl hydrocarbon receptor in MDA-MB-231 cells treated with tranilast (ab120643), by ICC/IF. Increase in Aryl hydrocarbon receptor expression correlates with increased concentration of tranilast, as described in literature.
      The cells were incubated at 37°C for 24h in media containing different concentrations of ab120643 (telmisartan) in DMSO, fixed with 100% methanol for 5 minutes at -20°C and blocked with PBS containing 10% goat serum, 0.3 M glycine, 1% BSA and 0.1% tween for 2h at room temperature. Staining of the treated cells with ab84833 (5 µg/ml) was performed overnight at 4°C in PBS containing 1% BSA and 0.1% tween. A DyLight 488 goat anti-rabbit polyclonal antibody (ab96899) at 1/250 dilution was used as the secondary antibody. Nuclei were counterstained with DAPI and are shown in blue.

    References for Tranilast (ab120643)

    This product has been referenced in:
    • Shiota N  et al. The anti-allergic compound tranilast attenuates inflammation and inhibits bone destruction in collagen-induced arthritis in mice. Br J Pharmacol 159:626-35 (2010). Read more (PubMed: 20067475) »
    • Jin D  et al. Tranilast, an anti-allergic drug, possesses antagonistic potency to angiotensin II. Eur J Pharmacol 361:199-205 (1998). Read more (PubMed: 9865509) »
    • Hishikawa K  et al. Tranilast restores cytokine-induced nitric oxide production against platelet-derived growth factor in vascular smooth muscle cells. J Cardiovasc Pharmacol 28:200-7 (1996). Read more (PubMed: 8856474) »

    See 0 Publications for this product

    Product Wall

    There are currently no Abreviews or Questions for ab120643.
    Please use the links above to contact us or submit feedback about this product.

    Please note: All products are "FOR RESEARCH USE ONLY AND ARE NOT INTENDED FOR DIAGNOSTIC OR THERAPEUTIC USE, NOT FOR USE IN HUMANS"